Cargando…
HIF1α Regulates IL17 Signaling Pathway Influencing Sensitivity of Taxane-Based Chemotherapy for Breast Cancer
Hypoxia-induced chemotherapy resistance is the main hindrance for solid tumor treatment. Hypoxia inducible factor-1α (HIF1α), an adaptive gene of hypoxia condition, played an important role in affecting chemotherapy sensitivity for many cancer types and various therapeutic regimens. This study focus...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8476907/ https://www.ncbi.nlm.nih.gov/pubmed/34595177 http://dx.doi.org/10.3389/fcell.2021.729965 |
_version_ | 1784575722243751936 |
---|---|
author | Dai, Huijuan Sheng, Xiaonan Wang, Yaohui Zhou, Liheng Lin, Yanping Du, Yueyao Yang, Fan Sha, Rui Peng, Jing Yao, Linli Yin, Wenjin Lu, Jinsong |
author_facet | Dai, Huijuan Sheng, Xiaonan Wang, Yaohui Zhou, Liheng Lin, Yanping Du, Yueyao Yang, Fan Sha, Rui Peng, Jing Yao, Linli Yin, Wenjin Lu, Jinsong |
author_sort | Dai, Huijuan |
collection | PubMed |
description | Hypoxia-induced chemotherapy resistance is the main hindrance for solid tumor treatment. Hypoxia inducible factor-1α (HIF1α), an adaptive gene of hypoxia condition, played an important role in affecting chemotherapy sensitivity for many cancer types and various therapeutic regimens. This study focused on the impact of HIF1α on predicting response and survival of taxane-based neoadjuvant therapy (NAT) for breast cancer (BC) patients and the concrete mechanism that HIF1α mediated paclitaxel chemo-insensitivity. We evaluated HIF1α expression immunohistochemically from biopsies of 108 BC patients receiving paclitaxel–cisplatin NAT. Univariate and multivariate logistic regression analysis revealed that high HIF1α expression led to lower rate of pathological complete response (pCR) and worse prognosis. Analysis of GEO datasets also indicated negative association between HIF1α expression and response of taxane-based NAT in BC patients. The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment of differential expression genes (DEGs) in different HIF1α expression groups from TCGA database showed that HIF1α participated in interleukin 17 (IL-17) signaling pathway. Correlation analysis suggested that HIF1α was positively related to the IL-17 pathway. CXC motif chemokine ligand 10 (CXCL10) was the only DEG in the IL-17 pathway inversely relating to NAT response. Experiments in vitro verified that HIF1α/IL-17 pathway influences paclitaxel sensitivity to BC cells. Correlation analysis between HIF1α/IL-17A/CXCL10 and infiltration of immune cells in BC uncovered that high expression of all the above three genes were positively correlated to neutrophil infiltration in BC. Collectively, our findings shed novel insight into the mechanism of chemotherapy resistance and implied that HIF1α inhibitor may be a promising drug combined with traditional chemotherapeutic drug to increase the chemotherapy efficacy. |
format | Online Article Text |
id | pubmed-8476907 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84769072021-09-29 HIF1α Regulates IL17 Signaling Pathway Influencing Sensitivity of Taxane-Based Chemotherapy for Breast Cancer Dai, Huijuan Sheng, Xiaonan Wang, Yaohui Zhou, Liheng Lin, Yanping Du, Yueyao Yang, Fan Sha, Rui Peng, Jing Yao, Linli Yin, Wenjin Lu, Jinsong Front Cell Dev Biol Cell and Developmental Biology Hypoxia-induced chemotherapy resistance is the main hindrance for solid tumor treatment. Hypoxia inducible factor-1α (HIF1α), an adaptive gene of hypoxia condition, played an important role in affecting chemotherapy sensitivity for many cancer types and various therapeutic regimens. This study focused on the impact of HIF1α on predicting response and survival of taxane-based neoadjuvant therapy (NAT) for breast cancer (BC) patients and the concrete mechanism that HIF1α mediated paclitaxel chemo-insensitivity. We evaluated HIF1α expression immunohistochemically from biopsies of 108 BC patients receiving paclitaxel–cisplatin NAT. Univariate and multivariate logistic regression analysis revealed that high HIF1α expression led to lower rate of pathological complete response (pCR) and worse prognosis. Analysis of GEO datasets also indicated negative association between HIF1α expression and response of taxane-based NAT in BC patients. The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment of differential expression genes (DEGs) in different HIF1α expression groups from TCGA database showed that HIF1α participated in interleukin 17 (IL-17) signaling pathway. Correlation analysis suggested that HIF1α was positively related to the IL-17 pathway. CXC motif chemokine ligand 10 (CXCL10) was the only DEG in the IL-17 pathway inversely relating to NAT response. Experiments in vitro verified that HIF1α/IL-17 pathway influences paclitaxel sensitivity to BC cells. Correlation analysis between HIF1α/IL-17A/CXCL10 and infiltration of immune cells in BC uncovered that high expression of all the above three genes were positively correlated to neutrophil infiltration in BC. Collectively, our findings shed novel insight into the mechanism of chemotherapy resistance and implied that HIF1α inhibitor may be a promising drug combined with traditional chemotherapeutic drug to increase the chemotherapy efficacy. Frontiers Media S.A. 2021-09-14 /pmc/articles/PMC8476907/ /pubmed/34595177 http://dx.doi.org/10.3389/fcell.2021.729965 Text en Copyright © 2021 Dai, Sheng, Wang, Zhou, Lin, Du, Yang, Sha, Peng, Yao, Yin and Lu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cell and Developmental Biology Dai, Huijuan Sheng, Xiaonan Wang, Yaohui Zhou, Liheng Lin, Yanping Du, Yueyao Yang, Fan Sha, Rui Peng, Jing Yao, Linli Yin, Wenjin Lu, Jinsong HIF1α Regulates IL17 Signaling Pathway Influencing Sensitivity of Taxane-Based Chemotherapy for Breast Cancer |
title | HIF1α Regulates IL17 Signaling Pathway Influencing Sensitivity of Taxane-Based Chemotherapy for Breast Cancer |
title_full | HIF1α Regulates IL17 Signaling Pathway Influencing Sensitivity of Taxane-Based Chemotherapy for Breast Cancer |
title_fullStr | HIF1α Regulates IL17 Signaling Pathway Influencing Sensitivity of Taxane-Based Chemotherapy for Breast Cancer |
title_full_unstemmed | HIF1α Regulates IL17 Signaling Pathway Influencing Sensitivity of Taxane-Based Chemotherapy for Breast Cancer |
title_short | HIF1α Regulates IL17 Signaling Pathway Influencing Sensitivity of Taxane-Based Chemotherapy for Breast Cancer |
title_sort | hif1α regulates il17 signaling pathway influencing sensitivity of taxane-based chemotherapy for breast cancer |
topic | Cell and Developmental Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8476907/ https://www.ncbi.nlm.nih.gov/pubmed/34595177 http://dx.doi.org/10.3389/fcell.2021.729965 |
work_keys_str_mv | AT daihuijuan hif1aregulatesil17signalingpathwayinfluencingsensitivityoftaxanebasedchemotherapyforbreastcancer AT shengxiaonan hif1aregulatesil17signalingpathwayinfluencingsensitivityoftaxanebasedchemotherapyforbreastcancer AT wangyaohui hif1aregulatesil17signalingpathwayinfluencingsensitivityoftaxanebasedchemotherapyforbreastcancer AT zhouliheng hif1aregulatesil17signalingpathwayinfluencingsensitivityoftaxanebasedchemotherapyforbreastcancer AT linyanping hif1aregulatesil17signalingpathwayinfluencingsensitivityoftaxanebasedchemotherapyforbreastcancer AT duyueyao hif1aregulatesil17signalingpathwayinfluencingsensitivityoftaxanebasedchemotherapyforbreastcancer AT yangfan hif1aregulatesil17signalingpathwayinfluencingsensitivityoftaxanebasedchemotherapyforbreastcancer AT sharui hif1aregulatesil17signalingpathwayinfluencingsensitivityoftaxanebasedchemotherapyforbreastcancer AT pengjing hif1aregulatesil17signalingpathwayinfluencingsensitivityoftaxanebasedchemotherapyforbreastcancer AT yaolinli hif1aregulatesil17signalingpathwayinfluencingsensitivityoftaxanebasedchemotherapyforbreastcancer AT yinwenjin hif1aregulatesil17signalingpathwayinfluencingsensitivityoftaxanebasedchemotherapyforbreastcancer AT lujinsong hif1aregulatesil17signalingpathwayinfluencingsensitivityoftaxanebasedchemotherapyforbreastcancer |